Physician profile
Paul R Maynard
NPI 1538118575
$861.46
in general payments reported to CMS, 2019-2025
14 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $94.68 · 2021: $321 · 2022: $20.33 · 2023: $60.86 · 2024: $47.23 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $305.66 | 2020-2021 | |
| Djo, LLC | $149.94 | 2025 | Cmf |
| Smith+Nephew, INC. | $73.16 | 2019-2025 | Pico |
| Heraeus Medical, LLC. | $60.86 | 2023 | Palacos |
| Depuy Synthes Sales INC. | $58.63 | 2019-2024 | Monovisc |
| Convatec INC. | $42.22 | 2020-2022 | |
| Catalyst Orthoscience | $34.67 | 2021 | |
| Pacira Therapeutics, INC. | $32.58 | 2021 | |
| Olympus America INC. | $28.57 | 2019 | |
| Fidia Pharma USA INC. | $17.99 | 2024 | Hymovis |
| Elite Orthopedics, LLC | $15.17 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.13 | 2025 | Exparel |
| Bioventus LLC | $13.81 | 2025 | Exogen Ultrasound Bone Healing System |
| Ferring Pharmaceuticals INC. | $13.07 | 2024 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Maynard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.